StockData
Oculis Holding AG logo

Oculis Holding AG (OCS) stock

OCSNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as OCSAW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 20-F on Mar 4, 2026Score 1/30
$7.39−0.12 (-1.60%)

Close on Nov 18, 2026Market cap $444.06MP/E –Yield –

Oculis r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was CHF 57.09M, up 9.6% from the year before. The highest annual figure on record is CHF 57.09M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025CHF 57.09M+9.6%
FY2024Dec 31, 2024CHF 52.08M+78.1%
FY2023Dec 31, 2023CHF 29.25M+31.6%
FY2022Dec 31, 2022CHF 22.22M+132.3%
FY2021Dec 31, 2021CHF 9.57M+2.5%
FY2020Dec 31, 2020CHF 9.34M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026CHF 15.28M–
Q2 FY2025Jun 30, 2025CHF 14.91M–
Q2 FY2024Jun 30, 2024CHF 16.47M–
Q2 FY2023Jun 30, 2023CHF 6.20M–

More Oculis figures

See a number that looks wrong?